| Wissenschaftl. Titel | A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety' Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9L50 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| Erkrankung |
Kopf-Hals:
Kopf-Hals-Tumoren:
Zweitlinie oder höher
|
|
Krankenhaus Nordwest GmbH
(Rekrutierung beendet) Institut für klinisch-onkologische Forschung Prof. Dr. med. Salah-Eddin Al-Batran Tel: 069 / 7601 4420 albatran@khnw.de |
|
| Kurzprotokoll | Kurzprotokoll |
erstellt 11.07.2016 Steffen Kemmerzehl
geändert 16.08.2022 Student Studienregister